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The study was conducted at Tshwane District Hospital (TDH) in Pretoria,
Gauteng Province, South Africa. TDH is a district hospital that provides
comprehensive primary level health care services to patients from a large part of 
the greater Tshwane Municipality (estimated population of 2,2 million people).
TDH forms part of the University of Pretoria‟s training complex for pre- and post-
graduate health professionals. The HIV clinic at TDH was started in June 2004
and, since opening their doors, has treated 5 870 patients. Currently 3 756
patients are still receiving HAART, 1 297 (22%) have been lost to follow-up and
296 have died. 
The aim of this retrospective cohort study was to identify factors that may predict
the outcome of individuals started on HAART and to formulate a guideline to
assist health care workers to identify and better support patients more at risk of
mortality or poor outcome.
Patients meeting the inclusion criteria were older than 18 years and started on
HAART at TDH HIV clinic from June 2004 up to and including June 2009. A 
systematic random sampling method was employed for the selection of a
representative sample, sampling every 10th patient file. A univariate statistical
analysis approach was followed.
This study aimed to identify factors/variables that could explain the variation in 
CD4 count among severe immune suppressed patients. Male gender, low body 
weight, high viral count, low hemoglobin level, high AST and ALT levels 
explained some of the variation in CD4 count and were more prominent in the 














Secondly this study aimed to identify factors that could predict the outcome of 
patients started on HAART. Factors that showed some significance were 
unemployment, lower body weight, a low CD4 count, high viral count and low 
hemoglobin level. Owing to an overall low mortality rate of 5,4%, these factors 
did not show to have any predictive value. HIV is a life-threatening illness with an 
unpredictable course. This low mortality rate shows that HAART is a very 
effective palliative treatment modality which has the potential to improve 
morbidity and prolong survival in patients with HIV. 
The third aim of this study was to determine the correct mortality rate among lost
to follow-up patients. It showed a 39% mortality rate among lost to follow-up 
patients.
Better surveillance and follow-up care may further improve the outcome of 
patients initiated on HAART. Strategies that could be looked at may be a DOT 
(direct observed treatment programme) system for HIV (as in the case of
tuberculosis) or home-based care may also assist to better monitor patients at














CHAPTER 1 – INTRODUCTION 
1.1 HIV Epidemic 
An epidemic is defined as a rate of disease that reaches unexpectedly high 
levels, affecting a large number of people in a relatively short time1.
HIV is a global epidemic with an estimated 40,3 million people infected with the 
virus worldwide, of which a large percentage (65%) live in Sub-Saharan Africa2. 
Aids-related illnesses is the leading cause of adult mortality and morbidity in this
region1. It is estimated that 3 to 4 million people are infected each year and 2 to 3
million people in Sub-Saharan Africa die of Aids annually2.
In Africa, more than in the rest of the world, there has been denial of the
seriousness of the HIV epidemic which has lead to a delay in effective response
to the epidemic. HIV highlights “global inequalities and its impact is felt more
profoundly in poor countries”1. These inequalities include the quality, accessibility 
and availability of health care as well as necessary medications. 
African countries also experience high levels of poverty. Poverty leads to
malnutrition and other diseases associated with a poor quality of living, for 
example cholera and other gastro-intestinal diseases. These factors have an
impact on the overall health of patients living with HIV infection as well as the
speed at which HIV disease progress. Overcrowding, which is a common
phenomena in poorer countries, leads to a higher risk of respiratory infections
such as tuberculosis and other lower respiratory tract infections. The film
„Yesterday‟ realistically portrays the HIV problem and some of the inequalities
within the African setting that I have just mentioned and is therefore included to
highlight the difficulties faced by people who are HIV-positive3.
I would like to discuss some of the struggles the main character in this film faced. 














doctor at the local clinic, a few kilometres from her home. She had to walk all the 
way to the clinic. Upon her arrival at the clinic she was told to go home because 
the doctor was going to see only a certain number of patients and she was too 
late. This went on for weeks and finally a friend paid for a taxi so that she could 
get to the clinic earlier. After appropriate investigations and counselling she was 
told that she was HIV-positive. She was also advised to disclose this to her 
husband (her only sexual partner) who was working in the city and to advise him 
to get tested. When she told him about her diagnosis he physically abused her.  
Later in the film the husband came home with Aids and asked for her
forgiveness. The women in the village started to suspect that he was HIV-positive
and tried to force her to leave the village due to her husband‟s condition. This
reaction was fuelled by their own ignorance about HIV transmission and their fear
of contracting the disease. Desperate she tried to have her husband admitted to
the local hospital, but was turned down because the hospital was full and had a
waiting list. In the end this lady built a „home‟ with scrap metal, away from the
village, where she took care of her dying husband. I think this film portraits the
realities many of our patients are facing in the African context, where resources
are limited and health care system is failing our patients.
1.2 HIV Natural history and staging
“The human immunodeficiency virus (HIV) primarily infects and destroys cells in
the immune system, particularly CD4 (helper) T-lymphocytes, causing profound
immune suppression that gradually develops over a period of years and
ultimately renders the patient vulnerable to opportunistic infections and
malignancy. In addition to the effects on the immune system, HIV also infects
nerve, renal and bone marrow cells with clinical important consequences”4.
A person infected with HIV will usually go through various clinical stages over a 
period of time. The stages of HIV infection include “viral transmission, acute HIV 














symptomatic HIV infection/Aids-defining complication, and death”5. This is not a 
linear progression and death can be delayed for years. The clinical condition of 
patients can be improved that restores health and active living by Highly Active 
Antiretroviral Treatment (HAART). 
The disease may progress more rapidly in individuals who have a poor health 
status, such as “chronic disease, recurrent infections, anaemia, malnutrition or 
nutritional deficiency, repeated pregnancies without adequate recovery between 
pregnancies, malaria or TB”. These are all more common in the sub-Saharan 
Africa population2.  
1.3 HIV and psycho-social concerns 
HIV is a life-threatening illness with an unpredictable course. Over an above the
complex clinical picture is the emotional, social and economic impact of this
pandemic.6. Thulisili Ganyaza-Twalo and John Seager did a literature review on
poverty and HIV/Aids and found that at social level, households have to deal with
the issues of stigmatisation, social exclusion, disintegration of family structures
and being overburdened with care and support roles7. They also found that at
economic level, families have to deal with medical costs, funeral costs and loss
of income if the breadwinner passes away. Sometimes Sub-Saharan Africa has
households with more than one individual infected with HIV and families face
multiple losses. Unfortunately rolereversal with children looking after sick parents
and becoming the „care takers‟ is also a reality. 
An alarming increase in the number of orphans as a result of the HIV epidemic is 
also cause for concern. An 'orphan' is defined by the United Nations as a child 
who has 'lost one or both parents'. Worldwide, it is estimated that more than 15 
million children under 18 have been orphaned by Aids. Around 11,6 million of 














Also of concern, as pointed out by Thulisili Ganyaza-Twalo and John Seager, is 
the infringement of children‟s rights with regard to education, food, nutrition, 
health and other issues7. The HIV epidemic not only affects households but also 
the country‟s economy in general. When large numbers of the workforce is 
infected, a decrease in daily productivity and an increase in sick leave taken is 
observed. The country‟s health care is also affected due to the increased burden 
of care faced in the health care setting.  
There is no curative treatment modality known at this point, but HAART shows 
promising results in controlling the course of the illness. HAART transforms HIV
from a chronic disease to a terminal illness. It reduces the burden of disease and
can improve a patient‟s quality of life.
1.4 HAART 
Highly active antiretroviral therapy (HAART) is a treatment modality aimed at 
stopping the progression of HIV disease by reducing the HIV viral load and 
thereby allowing for recovery of the immune system and subsequent reduction of 
HIV-related illness4.  
Current South African guidelines recommend initiation of HAART9:
A. Patients eligible to Start HAART
Patients with a CD4 count <200 cells/mm3 irrespective of clinical stage or CD4
count <350 cells/mm3 in patients with TB/HIV or pregnant women or World
Health Organisation (WHO) Clinical Staging System4 stage IV irrespective of 
CD4 count (Appendix 1) or MDR/XDR-TB irrespective of CD4
B. Patients requiring HAART initiation within 2 weeks of being eligible)
Pregnant women eligible for lifelong HAART or patients with very low CD4 















“Ideally HAART should be commenced before very severe immune suppression 
has developed, as significant immune recovery may not occur once this point has 
been reached”4.  
 
The WHO, however, recommends that HAART should commence before the 
CD4 count drops below 350 cells/ul. Recommendations from the European 
guidelines for the initiation of therapy in naïve HIV-infected patients are as 
follows: 
 CD4 <200 cells/mm3: treatment recommended without delay 
 CD4 201-350 cells/mm3: treatment recommended 
 CD4 350-500 cells/mm3: treatment recommended when: 
o hepatitis C or B co-infection 
o HIV associated nephropathy 
o specific organ deficiency 
o viral load > 105 and/or CD4 decline > 50-100 mm3/year 
o pregnancy 
o high cardiovascular risk 
o malignancy  
 CD4> 500 cells/mm3: treatment should generally be deferred10 
 
1.5 Managing HIV as a chronic disease 
With the introduction of HAART HIV is now a manageable chronic disease. 
Management of people with HIV/Aids now includes HIV viral suppression with 
HAART therefore delaying the onset of serious immune deficiency, opportunistic 
infections and Aids; and managing and supporting patients to adhere strictly to 
HAART drug regimen. It also includes avoiding and managing drug side-effects 
and toxicity as well as avoiding and managing emerging ARV drug resistance 
and the prevention of mother to child HIV transmission with the use of HAART. 
Counselling of affected people, supporting and caring for people who are ill and 
dying and implementing preventative strategies to control the spread of HIV are 














These above guidelines are based on palliative care principles. It is therefore 
important to look at the definition of palliative care. Prior to the introduction of 
HAART as a treatment modality palliative care had a natural place in Aids care. 
The presence of ongoing symptoms, the significant social problems and 
hospice‟s long association with Aids patients may however justify a palliative 
perspective. 
1.6 WHO definition of palliative care 
Palliative care is defined by the WHO as an approach that improves the quality of
life of patients and their families facing problems associated with life-threatening
illness, through the prevention and relief of suffering, the early identification and
impeccable assessment and treatment of pain and other problems, physical, 
psychosocial and spiritual. 
Palliative care:  
 Provides relief from pain and other distressing symptoms;
 Affirms life and regards dying as a normal process; 
 Intends neither to hasten or postpone death;
 Integrates the psychosocial and spiritual aspects of patient care;
 Offers a support system to help patients live as actively as possible until
death; 
 Offers a support system to help the family cope during the patient‟s illness
and in their bereavement; 
 Uses a team approach to address the needs of the patient and their families,
including bereavement counselling, if indicated; 
 Will enhance quality of life, and will also positively influence the course of
illness; and 
 Is applicable early in the course of illness, in conjunction with other therapies















therapy, and those investigations needed to better understand and manage 
distressing clinical complications‟11.  
 
As HIV is a chronic disease marked by pain, distressing symptoms and possibly 
death, palliative care is important in HIV care.  Palliative care also focuses on 
emotional, psychosocial and spiritual aspects of patients‟ care, as mentioned 
above, which plays a big part in the life of the patient living with HIV, as well as 
the lives of their families. Positively influencing the course of HIV is also 
important and here palliative care can also play an important role. 
 
1.7 Motivation/Statement of the problem 
Resource limitations has led to HAART being available only to South Africa‟s 
public sector once immune suppression has developed (as defined by a CD4 
<200 cells/ul) although a study done by Jean B, Nachega MD, of the Harvard 
School of Public Health in Boston, and colleagues of 6 833 HIV-positive adults in 
South Africa who started HAART through a private sector programme, showed 
that high adherence to HAART in resource poor settings is associated with 
reduced overall direct health care cost12. 
 
Stephan Lawn also found that the mortality rate after starting treatment with a 
CD4 count below 100 and Aids-related illness the 48-month cumulative mortality, 
was 24,8%13. 
 
Due to late diagnosis or late presentation, many people are starting HIV 
treatment very late, with CD4 counts often below 50 cells/ul. These individuals 
are much more likely to develop serious illnesses or die soon after starting 
treatment.  
 
The ideal would be the initiation of HAART earlier, but in a country with large 
numbers of infected patients, who present at a very late stage, it will be 














estimated antiretroviral therapy coverage in HIV-infected people aged 15-49 
years in 2004 in South Africa was 7% (number of people needing ART 837 000 
and number of people receiving ART 37 000-62 000) 14.  
This leads to the question of whether there are factors that can be identified that 
will identify more vulnerable patients and will predict the outcome, as this will 
then enable us to look at strategies to support them better and, in doing, so 
better the outcome of treatment. 
Factors that have been identified as predictors of outcome for patients starting on
HAART include age, weight at HAART initiation, total CD4 count, viral load at
HAART initiation, hemoglobin level, platelet count, liver function (with emphasis
on AST and ALT levels), serum-albumin, the presence of opportunistic infections
at initiation of HAART, the presence of co-morbid or HIV-related malignancies
and emotional and social support15, 16, 17, 18.
1.8 Study site background 
The study was conducted at Tshwane District Hospital (TDH) in Pretoria,
Gauteng Province, South Africa. TDH is a district hospital that provides
comprehensive primary level health care services to patients from a large part of 
the greater Tshwane Municipality (estimated population of 2,2 million people).
TDH forms part of the University of Pretoria‟s training complex for pre- and post-
graduate health professionals. The HIV clinic at TDH was started in June 2004
and, since opening their doors has treated 5 870 patients. Currently 3 756
patients are still receiving HAART, 1 297 (22%) have been lost to follow-up and
296 have died. 
In another study, Bisson et al. analysed a large public antiretroviral therapy 
programme in Sub-Saharan Africa and documented lost to follow-up 16,6% with 
a substantial death rate of 58,8% among these patients soon after initiating 















defaulted treatment, this can serve as a marker for non-compliance, as non-
compliance leads to poor patient outcomes. 
 
This also illustrates how uncertainty about the death rate among patients lost to 
follow-up can result in both inaccurate estimates of survival and biased estimates 
of risk factors for death after HAART initiation. The question arises whether this 
problem will be less prominent if more vulnerable patients can be identified and 
strategies put in place to better support them? 
 
1.9 Aim of the study 
The aim of this retrospective study is to identify characteristics of patients with 
low CD4 count and to determine if there was any correlation between a low CD4 
count and death. 
 
 1.10 Objectives of the study 
The main objectives of the study are to: 
 Identify the profile of patients with low CD4 count vs. the profile of patients 
with CD4 >50 cells/mm3; 
 Identify factors that predict outcomes of HAART in immune suppressed 
patients in a resource-limited setting; 
 Determine the corrected mortality rate once lost to follow-up patients‟ data are 














CHAPTER 2 – LITERATURE REVIEW 
With HIV being a global epidemic  and millions of people being infected 
worldwide and 65% living in sub-Saharan Africa it estimated that a further 3 to 4 
million people are infected each year and 2 to 3 million people in sub-Saharan 
Africa die of Aids annually2.
“Ideally HAART should be commenced before very severe immune suppression
has developed as significant immune recovery may not occur once this point has
been reached”4. Resource limitations have led to HAART being available to
South Africa‟s public sector patients only once immune suppression has
developed.
Important factors that have been identified as predictors of outcome for patients
starting on HAART include age, weight, total CD4 count and viral load at HAART 
initiation, hemoglobin level, platelet count, liver function (with emphasis on AST 
and ALT levels), serum-albumin, the presence of opportunistic infections at
initiation of HAART, the presence of co-morbid or HIV-related malignancies and
emotional and social support.
According to the SOLVE methodology five psychosocial issues: stress, violence, 
alcohol and drug use, HIV/AIDS and tobacco consumption are interrelated. 
Evidence shows that psychosocial issues occur in cluster form. The stress of HIV 
positive status increased tobacco smoking, alcohol use or illicit drug use. There 
is a shown bidirectional interrelation. These psychosocial issues can have a 
negative impact on outcome of treatment by having an effect on adherence or 
patient‟s general health. 20 
A literature review on the topic of HAART initiation and outcomes focused on 














CD<200 cell/ul and certain specific predictive factors, including anaemia, weight 
at initiation, the presence of thrombocytopenia, co-morbid diseases, age and 
adherence. Optimal criteria for the initiation of HAART, as well as the mortality 
rate in general, were also reviewed. 
The literature review will focus first on the effect of HAART on the general 
mortality rate and then focus on the different predictors of outcome. 
The studies that were reviewed in this literature review were obtained through a 
Medline, advanced Google and an African health line search on the internet 
spanning a research period from 2000 up to now. 
2.1 Mortality rate
It is well established that there is an improvement in the mortality rate of HIV/Aids
patients receiving HAART.
Palella et al. report on the research study the Khayelitsha ARV treatment
project21 which was initiated to demonstrate that treating HIV/Aids with ARV 
drugs in a primary health care setting and in a resource-limited environment is
feasible and replicable. Research was done in Khayelitsha with a study
population of 288 between April 2001 to late 2002 and showed the following
changes in clinical measures after one year of HAART:
 Mean weight gain of 10 kg;
 Decline in frequency of opportunistic infections;
 Viral load suppression;
 Mean overall CD4 count increase of 221 cell/mm3; and
 84% survival at 18 months of treatment (decreased mortality rate).
A prospective observational cohort study from 8 clinics in the USA with 1 022 
participants, done by Palella et al., showed a decline in death rate from a 
quarterly mean of 29,5 deaths/100 person years of observation in 1995 (prior to 















by the fourth quarter of 1996 (when HAART utilisation had a prevalence of 65,7% 
of their patient cohort) 15. 
 
A descriptive study done at St. Paul‟s Hospital, Vancouver, Canada by Wood et 
al., evaluated whether non-immune-based factors, such as physician experience 
and adherence, could affect survival among HIV-infected adults starting 
HAART22. A study population 1 416 was analysed and they concluded that 
survival rates following the initiation of HAART are “dramatically improved among 
patients starting with CD4 counts <200 x 106 cell/l once adjusted for conservative 
estimates of physician experience and adherence”.  The overall Aids mortality 
rate for patients after initiating HAART was found to be 7,8%. 
 
Park et al. conducted an observational cohort study at a tertiary referral hospital 
in South Korea23.  Their objective was to determine whether adherence to clinic 
visits early after initiation of HAART is predictive of long-term clinical outcome.  
Their study population was smaller (387) than the previously mentioned studies‟ 
populations, but still large enough to be significant.  The patients were followed 
up for at least 1 year after initiation of HAART and the study was conducted over 
a 6 year period.  The mean time to death was 35 months after initiating HAART 
and the mortality rate 2%. 
 
Statistics South Africa also showed a 1,8% drop in deaths from 2006 to 2007. 
Whether this is due to the government‟s Aids treatment programme is still to be 
determined24. 
 
Although all of the studies discussed were done in different settings (from first-
world to resource-limited settings) the conclusions were the same: initiation of 
HAART decreases overall mortality of HIV/Aids patients.  
 















Norval listed the following clinical signs and symptoms in the Manual of Palliative 
Care in Aids25 to often be associated with decreased survival time: 
 Poor performance status (>50% of day spend in bed)
 Chronic diarrhoea and rapid loss of weight or wasting
A prospective community-based cohort study on early mortality among adults
accessing a community-based antiretroviral service in South Africa (Cape Town, 
South Africa), done by Lawn et al., found wasting syndrome, TB, acute bacterial
infections, malignancies and immune reconstitution disease were the major
causes of death. Most early in-programme deaths occurred among patients with
advanced immuno deficiency who had not yet initiated ART16.
The previously discussed article by Palella et al. also described the presence of 
co-morbid conditions, such as substance abuse and addiction as poor prognostic
factors15.
2.2.2 Anaemia 
Mocroft et al. conducted an observational, prospective cohort analysis of 6 725
HIV patients from across Europe26. The objective was to describe changes in
haemoglobin over time and to determine the joint prognostic value of the current
haemoglobin, CD4 count and viral load. They found anaemia to be one of the
clinical manifestations of auto-immunity and one of the most common
hematological abnormalities affecting 70-95% of HIV-positive individuals. An
association with increased risk of death was also found.
A study done by D Brittan27, as well as various handbooks on HIV infection 4, 6, 28
reports that the anaemia associated with HIV infection is “characterised as 
normochromic, normocytic with a low reticulocyte count” 4.  This is similar to the 















Johannessen et al. ask the question whether the “association between anaemia 
and mortality is casual or whether anaemia is rather a marker of progressive HIV 
disease”17. They conducted a cohort study of 320 treatment-naïve Tanzanian 
patients and found mortality to be at 19,2% within 3 months after initiating 
HAART and also that anaemia was a strong independent predictor of morality. 
 
Anaemia was also found to be a feature of opportunistic infections. Some 
etiologies mentioned in their study included mycobacterium infections, parvovirus 
B19, micronutrient deficiencies, immunological myelosuppression, impaired 
erythropoietin production and blood loss from intestinal opportunistic disease. 
 
Other causes of anaemia in HIV patients seen in the literature include 
myelosuppressive drugs as well as heamolysis2, 6, 5.  
 
2.2.3 Weight loss 
The wasting syndrome has become increasingly recognised in adults infected 
with HIV in the United States and at present accounts for approximately 18% of 
initial Aids-defining conditions. Weight loss, with or without associated symptoms, 
has been described in many people with advanced HIV infection29. 
 
Primary HIV/Aids care by C Evian2 list tuberculosis, diarrhoea, Pneumocystis 
carinii infection, lymphoma or HIV infection itself as common causes for weight 
loss. Weight loss is therefore often seen as a sign of an underlying opportunistic 
infection or a sign of advanced HIV infection. 
 
Other HIV-related textbooks mention more factors which may also be involved in 
causing weight loss in HIV patients4, 28.  These factors may include malabsorption 
associated with infective diarrhoea, increased metabolic rate, decreased intake 
due to anorexia, oropharyngeal or esophageal disease, economic reasons for 
















Wheeler et al.29 conducted a community-based cohort study of 2 382 HIV-
infected adults with all participants having a CD4 count of <500 cells/mm3. The 
study concluded that mild (less than 5%) or moderate (5% to 10% of body weight 
over a 4-month period in study) weight loss in an HIV-infected patient was 





The incidence of opportunistic infections after the initiation of HAART in 
advanced Aids patients with very low CD4 cell counts is high. Immune 
reconstitution inflammatory syndrome (IRIS) could explain why this is observed. 
Two forms of IRIS are discussed in literature reviewed. The first one mentioned 
is where an immune-suppressed individual is unable to respond to an 
opportunistic infection, then after the initiation of HAART an inflammatory 
immune response occurs against the pathogen and resulting in worsening of the 
clinical condition of the patient also referred to as “unmasking”. The second form 
mentioned in the literature referred to as “paradoxical” is when deterioration in 
clinical condition is observed due to a raised inflammatory response to an 
antigen that was treated or controlled30.  
 
A prospective multicentre study was conducted by Sungkanuparph et al.31 to 
investigate the incidence and spectrum of opportunistic infections after the 
initiation of HAART in advanced Aids patients with very low CD4 cell counts. 
Sixty patients with successful HAART treatment, which raised the median CD4 
cell count from 9 to168 cell/µl at 48 weeks, were studied. The study found that 
tuberculosis was the most common opportunistic infection in the populations 
studied. Other opportunistic infections were Mycobacterium Avium complex 
infection, relapsed cryptococcal meningitis, herpes zoster, toxoplasmosis and 
















Koenig et al. analysed mortality among 201 patients with Aids and tuberculosis in 
Haiti32. They found that patients who received a diagnosis of tuberculosis during 
the first 3 months after the initiation of antiretroviral therapy were 3,25 times more 
likely to die than other patients with Aids and tuberculosis. It was concluded that 
failure to recognise active tuberculosis at initiation of antiretroviral therapy lead to 
increased mortality.  Therefore, active TB that is not recognised when ART is 
started may, in part, explain the high mortality rate observed among patients with 
Aids in resource-poor settings. 
 
2.2.6 Age 
Most of the epidemiological features of older HIV-infected patients were 
determined before the introduction of HAART in 1996.  Since then HAART has 
been reported to have a “less beneficial effect on the immunological outcome in 
older patients”33.  A study conducted by Adler et al.34 on HIV infection and aging 
describes mechanisms to explain the accelerated rate of progression in the older 
patient and Operalski et al.35 on the influence of age, viral load and CD4+ count 
in the rate of progression of HIV-1 infection to Aids. Both showed older 
individuals to have a more severe HIV disease course and a shorter survival rate. 
 
In contrast to the studies done by Adler et al. and Operalski et al. recent studies  
(during the HAART era) showed that despite a higher risk of adverse events in 
older patients, high therapy adherence and a successful immunological response 
in older patients lead to a disease outcome comparable to that of younger 
patients.  Such recent studies include the retrospective observational cohort 
study conducted by Silverberg et al.36, in which changes in HIV clinical markers 
after HAART initiation were compared among 2 259 patients aged 18 to 39 years 
(reference group), 1 834 patients aged 40 to 49 years, and 997 patients 50 years 
or older enrolled in an integrated health care system.   Another recent study is 
the prospective case-control study done by Tumbarello et al.33 on older HIV-














HAART experienced a successful immunological response comparable to 
younger individuals. 
Although the size of the study population and the follow-up time of these studies 
differed considerably, the outcomes were the same, and thus the conclusion is 
that age is not a predictor of poor outcome on HAART. 
2.3 Optimal criteria for initiation of HAART 
The decision of when to initiate HAART is very important. On the one hand it
may be important to start treatment before clinical signs of immunodeficiency
develop but on the other hand it is important not to expose individuals to costly
treatment with possible severe adverse if not needed.
In 2000 Ormaasen et al.37 conducted an observational study at the Ulleval 
University Hospital in Oslo Norway on 162 treatment naïve Norwegian patients.
The objective was to identify optimal starting criteria regarding levels of CD4
cells and HIV(RNA) at initiation of HAART in chronically HIV-infected people.
They concluded, with very low confidence that CD4 count alone should influence
the decision of when to initiate HAART in asymptomatic patients. Their results
indicated that to delay treatment until CD4 drops below 0.2 x 109 cells/l in
asymptomatic patients, is advisable. These results were contradicted by an
observational study done by Kaplan et al. 38.
Given the fact that “observational studies are low in the hierarchy of evidence, 
the ideal study to answer the question of „when to start‟ would be a randomised 
control study, but the feasibility of such a trial may be limited by the willingness of 
patients and providers to participate and the sample size and length of time 
required to conduct a meaningful study”. For this reason Kaplan et al.38
conducted an observational in 2003 and 2 729 patients were included in this 
analysis. They concluded that patients with low CD4 counts (<200 cells/ul) when 















not experience the same clinical benefit as patients receiving treatment earlier 
(CD4 count 200-349 cells/ul).  
 
They suggest a discussion with patients whose CD4 count is between 200-349 
cells/ul and initiation of HAART is considered. The decision maker should take 
into account uncertainties regarding disease progression, development of drug 
toxicities, emergence of antiretroviral drug resistance and impact on quality of 
life. 
 
Wood et al.22 commented in 2003 that therapeutic guidelines advise that 200-350 
x106 cell/l may approximate an irreversible threshold beyond which response to 
therapy is compromised.  They conducted an observati nal study of 1 416 
treatment naïve Canadian patients who initiated triple therapy between 1996 and 
2000 to evaluate whether non-immune-based factors, such as physician 
experience and adherence, could affect survival among HIV-infected adults 
starting HAART. Their results showed improved survival rates following HAART 
initiation among patients with starting CD4 counts < 200 x 106 cells/l, once 
adjusted for physician experience and patient adherence. Inappropriate care of 
patients with advanced disease and patient non-adherence may be the strongest 
determinants of patient survival according to this study.  This supported the 
initiation of HAART for patients with CD4 counts < 200 x 106 cell/l. Current South 
African department of health guidelines use CD4 counts of < 350. 
 
2.4 Adherence 
As mentioned previously, the Khayelitsha ARV treatment project was initiated to 
demonstrate that HAART in the primary health care setting and in resource 
limited settings is feasible and replicable21. 
 
This programme used a patient selection process and patients were eligible for 
treatment if they were WHO stage III and IV and had a CD4 count of less than 















attendance were used to assess ability to adhere to HAART. A home visit was 
also done before initiating HAART to assess the family environment and for 
disclosure.  Progress was monitored weekly for the first two weeks, then two-
weekly up to the end of the second month and thereafter monthly.   
 
Factors included in this programme to further improve adherence were that 
patients had to have a treatment assistant who was someone living in the 
household, aware of the patient‟s status and willing to assist with medication if 
necessary. Individuals on HAART had to attend twice-monthly support groups 
and patients were also supplied with pill boxes, drug identifications charts, daily 
schedules, diaries and education material explaining the risks and benefits of 
HAART. They found that when simplified regimens with a low pill burden and a 
comprehensive individual support programme were combined, patients showed 
high levels of adherence to the medication. 
 
Park et al.23 conducted an observational cohort study in South Korea to evaluate 
whether one-year adherence to clinic visits after highly active antiretroviral 
therapy could be a predictor of clinical progress in HIV patients.  The authors 
showed in their study that in the year after HAART was initiated, the number of 
missed clinic appointments and the next clinic visit were significant risk factors for 
occurrence of subsequent Aids defining illness or death. When the total number 
of days that elapsed between missed appointments were >30 days, the risk of 
Aids progression was increased. Furthermore adherence to clinic visits was 
associated with clinical improvement irrespective of clinical category pre-HAART. 
 
Friedland et al.39 suggest that an unexplored strategy is to integrate HIV/AIDS 
and tuberculosis care and treatment, including highly active antiretroviral therapy, 
through existing tuberculosis directly observed therapy programs. This strategy 
could potentially improve the outcome for both diseases by addressing the 
related issues of inadequate access and infrastructure and the need for 















(DOT)” becomes more practical due to the availability of potent once-daily 
regimens. Where HAART by DOT was implemented in special community based 
care programs it showed promising results.  
 
Farmer et al.40 implemented HAART by DOT in Haiti showing great promise. 
Each patient was assigned to a community- health worker who observes the 
ingestion of medication, responds to the patient‟s and family concerns being in a 
supportive role. Monthly meetings where patients discuss their illness were also 
implemented with great success. 
 
2.5 Conclusions 
Different studies of different study types, size and locations (resource limited as 
well as unlimited) were reviewed.  Although the studies differed with regards to 
these aspects, the conclusions were similar making the results relevant to the 
South African setting as well as to my study.   
 
The literature reviewed indicates that the following predictors negatively influence 
the outcome of patients started on HAART: 
 Chronic diarrhoea, rapid weight loss or wasting; 
 The presence of co-morbid conditions; 
 TB, acute bacterial infections, malignancies and immune reconstitution 
disease; 
 Poor performance status; 
 Anaemia; 
 Poor adherence; and 
 Very low CD4 count 
 
Age in itself is found not to be a predictor of poor outcome of HIV patients on 
HAART. Under ideal circumstances even patients with very low CD4 counts can 
















However, further studies on this topic are recommended as the field of HIV 
medicine is a rapidly changing field and with HAART becoming more easily 
accessible the findings of the studies reviewed may well be supported or found 
















CHAPTER 3 – DATA AND METHODOLOGY 
 
3.1 Study design 
A retrospective cohort study to investigate the influence that certain identified 
factors has on mortality of HIV-positive patients on HAART. 
 
3.2 Study site  
All the data analysed come from the records of patients attending the HIV Clinic 
at Tshwane District Hospital (TDH) in Pretoria, Gauteng Province, South Africa. 
 
3.3 Study population  
Selection criteria 
Inclusion criteria: 
 Patients started on HAART at TDH HIV clinic from June 2004 up to and 
including June 2009 
 Patients older than 18 years of age 
 
Exclusion criteria: 
 Patients younger than 18 years of age 
 
 
3.4 Sampling design 
3.4.1 Sampling frame and procedure 
The target population for this study includes HIV-infected patients who started on 
HAART at the TDH HIV clinic during the period June 2004 to June 2009. 
According to medical records from TDH, a total of 5 870 valid charts/records 
were available from which data of 699 files were extracted for statistical analysis 
















A systematic random sampling method was employed for the selection of a 
representative sample, sampling every 10th patient file.  Each patient has a 
chart/record with a unique and distinctive identification number which was used 
for identifying patients. 
 
3.4.2 Sample size 
Ibrahim (2007), having conducted a study to evaluate the factors affecting the 
chance of survival/death status among HIV-positive people under a antiretroviral 
treatment programme at Adama Hospital located in Addis Ababa, Ethiopia, 
rightfully remarked that the selection of an appropriate sample size is an 
important decision to make, as a “too large sample implies a waste of resources 
while a too small sample reduces the usefulness of the results”41. Ibrahim (2007) 
furthermore noted that “in order to have an optimum sample size, there are a 
number of issues/points one has to take into account. Some of the issues are: 
 Objective of the research 
 Design of the research 
 Cost constraint 
 Plan for statistical analysis 
 Degree of precision required for generalisation 
 Degree of confidence required”41 
 
Accordingly, Ibrahim41 (2007) proposed the use of the following formula for 





Where n0 is the sample size, p the population proportion of death and d is the 


















SE is the standard error. 
 
And if the sampling is from a finite population of size N, then: 
 
 
Using the following parameters for this study, the sample size is calculated as: 
 
N = 5870 
Proportion of death (p) = 7% 
Absolute precision required (d) = 3% 
Sample size (n) = 265 
 
3.5 Data collection 
3.5.1 Data collection tools 
Data collection was done by using a data extraction sheet.  The data extraction 
sheet was designed in Microsoft Access and automatically imported data into an 
Excel spreadsheet. The data extraction sheet had built-in validations, drop-down 
menus with the appropriate choices and automatic calculations from the 
identification number (date of birth and age). Refer to Appendix 2.  This sheet 
was developed from discussions with colleagues (including the Head of the HIV 
Clinic at TDH), in consultation with the research supervisor and from a literature 
review on possible predictors of outcome.  
 
















3.5.2 Data collection method 
Before data were collected, approval from the following persons and departments 
was obtained: 
 The Head of the HIV Clinic at TDH (appendix 3)
 The CEO  at TDH (appendix 4)
 Human Research Ethics Committee approval from the University of Cape
Town and the University of Pretoria (Research Ethics Committee of the
Health Science Faculty). (Appendix 5)
Patient confidentiality was ensured by using locked cabinets to store information,
not making the patients identity public and by using a secure numerical system 
only known to the researcher. Patients‟ names and file numbers have no
correlation with the study number. The information required was recorded, by the
patient, in a Microsoft access database. All data used for the statistical sampling
was extracted without any fields that could potentially identify any patient, for
example the identity number, name or surname. The master file was in the
possession of the researcher and all cross referencing was done by the only
researcher.
The researcher, with the help of one field worker, collected data from every tenth
file of the patients (fitting our selection criteria) started on HAART since June
2004. All the patient records were available in the clinic itself. The field worker
was trained to use the data extraction sheet correctly and to use the numerical
system to ensure confidentiality. The electronic data extraction sheet had built-in
validations to limit human error while collecting data.
ID numbers of patients lost to follow-up were used to trace public records on the 
website of the department of home affairs to determine whether the patient was 
still alive or not. Records of patients who had died were further investigated at 
the department of home affairs to see if they had died of natural causes and what 
















3.6 Data analysis 
3.6.1 Model building 
In order to build a statistical model to predict the outcome of HAART, based on 
the data available, logistic regression is proposed.  Logistic regression is useful 
for situations in which you want to be able to predict the presence or absence of 
a characteristic or outcome based on values of a set of predictor variables. 
Although other multivariate techniques like multiple regression and discriminate 
analysis can also be used, it is best suited to models where the dependent 
variable is dichotomous (Norušis42, 1994).  Norušis also remarks that logistic 
regression requires far fewer assumptions than discriminant analysis, and even 
when the assumptions for discriminant analysis are satisfied, logistic regression 
still performs well42. 
 




Where z = b0 + b1x1 + b2x2 + ... bpxp 
 
The logistic equation can be rearranged into a linear form by converting the 
probability into a log odds. 
 
log [Prob(event)/Prob(no event)] = b0 + b1x1 + b2x2 + ... bpxp  
 
The dependent variable for the model will be survival status, where 1 = death and 
0 = alive.  The independent variables were defined from the other data extracted 
















The model building involved three steps.  The first step involved the evaluation of 
single variables for inclusion in the model.  This was done from the viewpoint of 
assessing the adequacy of each variable in terms of its statistical relationship 
with the dependent variable as well as its potential contribution to the overall fit of 
the model.  Analyses involved in this phase involved constructing of univariate 
tables, cross tabulations and significant tests of independent variables with the 
dependent variable in order to study variation in the data. 
 
The second step involved the construction of the statistical predictive model, in 
other words the logistic regression model. 
 
The final step was evaluation of the model by looking at its predictive capabilities.  
















CHAPTER 4 – RESULTS 
 
4.1 Introduction 
This study set out to address three research objectives, namely (1) to 
identify factors/variables that statistically explain variation in CD4 count 
amongst immune suppressed patients; (2) to identify factors that predict 
the outcomes of HAART in immune suppressed patients; (3) to determine 
the correct mortality rate amongst lost to follow-up patients. 
 
Chapter 4 presents the results obtained from the analysis pertaining to 
each of the objectives. 
 
4.2 Results regarding the objectives 
The outcomes of the statistical analysis are reflected under the relevant 
sub-headings below.  
 
4.2.1 Identify variables that explain variation in CD4 count 
The first objective aimed to identify those demographic, general health-risk 
behaviour (smoking and alcohol use) and health variables that statistically 
explain variation in CD4 count.  For the purpose of the analysis and to 
align with clinical relevance, patients were categorised into two groups, 
namely those with a CD4 count up to 50 and those with a count of more 
than 50.  The first group consisted of 87 patients and the second of 416. 
The results of the analysis are presented in tables 4.1 to 4.3.  Both Chi-
square Test of Independence and Mann-Whitney tests (for two 
independent samples) were performed. 
 
4.2.1.1 Demographic variables 
Inspection of the results show a significant difference in the proportional 















proportion of females in the second group (CD4>50) than in the first 
(CD4<50).  Conversely, the first group consisted of more males than the 
second group. The results also show significant differences in the mean 
weight recorded (p=0.000) between the two groups. 
Table 4.1: Significant tests on demographic variables by CD4 count 
 
DEMOGRAPHIC <50 50+ p-value Sig.
n = 87 n = 416
Gender
Male 43.7% 28.1%
Female 56.3% 71.9% 0.004 **
Age
Mean 39.3 39.4 0.801 -
Race
Black African 96.6% 96.2%
Other 3.4% 3.8% 0.859 -
Education
No education 26.4% 88.5%
Grade 0-5 5.7% 9.9%
Grade 6-7 11.5% 8.2%
Grade 8-12 52.9% 55.5%




Divorced/Widowed 10.3% 10.6% 0.754 -
Employed
Yes 48.3% 49.5%
No 51.7% 50.5% 0.833 -
Weight (kg)
























4.2.1.2 Risk behaviour variables 
The results from the Chi-square tests presented in table 4.2 show that 
CD4 count does not have any statistical relationship with the two general 
health risk-behaviour variables (smoking and alcohol use).  
 
Table 4.2: Significant tests on risk behaviour variables by CD4 count 
 
 
RISK BEHAVIOUR <50 50+ p-value Sig.

















4.2.1.3 Health variables 
Four of the health variables showed significant differences between the 
two CD4 groups, namely viral count (p=0.000), hemoglobin (p=0.000), 
AST (p=0.001) and ALT (p=0.016).  Significant only on a 90% level of 
confidence, TB (p=0.073) can also be regarded as explaining some 


















Table 4.3: Significant tests on health variables by CD4 count 
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4.2.2 Identify factors that predict the outcomes of HAART 
For the second objective, logistic regression was used to explore the 
association between the proposed independent variables and the 
response variable.  The response variables or death status was coded as 
follows: 1 indicates that the patient died while on HAART and 0 indicates 
survival of the patient. 
 
Inspection of the data reveal that the overall proportion of death while on 
HAART is low (Y = 5,4%). This may affect the predictive capabilities of the 
model.  It is therefore with this understanding that the univariate and 
multivariate analyses are made in this study. 
 
The first step in the analysis involves examining the relationship between 
the response variable and predictor variables.  The results are presented 
in tables 4.4 to 4.6. 
 
4.2.2.1 Demographic variables 
Inspection of the results shows that across employment (p=0,036), a 
significantly higher proportion of death cases were recorded among 
unemployed patients (7,5%) than among employed patients (3,2%).  The 
results also show significant differences in the mean weight recorded 
(p=0,013) between the response groups, with a lower average weight 
associated with death cases. 
 

















Table 4.4: Significant tests on demographic variables by status 
 
DEMOGRAPHIC Alive Dead p-value Sig.
Gender
Male n = 155 94.2% 5.8%
Female n = 348 94.8% 5.2% 0.771 -
Age
Mean n = 503 39.3 40.6 0.535 -
Race
Black African n = 484 94.6% 5.4%
Other n = 19 94.7% 5.3% 0.984 -
Education
No education n = 107 94.4% 5.6%
Grade 0-5 n = 46 95.7% 4.3%
Grade 6-7 n = 44 90.9% 9.1%
Grade 8-12 n = 277 94.6% 5.4%
Post Matric n = 29 100.0% 0.0% 0.566 -
Marital status
Single n = 349 94.8% 5.2%
Married n = 101 95.0% 5.0%
Divorced/Widowed n = 53 92.5% 7.5% 0.756 -
Employed
Yes n = 248 96.8% 3.2%
No n = 255 92.5% 7.5% 0.036 *
Weight (kg) n = 476 n = 27




























4.2.2.2 Risk behaviour variables 
For both risk behaviour variables, the proportion of deaths recorded did 
not differ significantly. 
 
Table 4.5: Significant tests on risk behaviour variables by status 
 
 
RISK BEHAVIOUR Alive Dead p-value Sig.
Smoker
Yes n = 45 91.1% 8.9%
No n = 285 94.0% 6.0%
Unknown n = 173 96.5% 3.5% 0.283 -
Alcohol use
Yes n = 44 93.2% 6.8%
No n = 286 93.7% 6.3%









4.2.2.3 Health variables 
Three of the health variables showed significant differences between the 
two response groups, namely CD4 count (p=0,001), viral count (p=0,025) 
and hemoglobin (p=0,000).  AST (p=0,051) could be considered 
significant at a 90% level of confidence.  For all other variables, either the 
proportion of deaths recorded did not differ significantly or no significant 
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A problem with any univariate analysis approach is the fact that it ignores 
the multivariate predictive capabilities of a collection of weakly associated 
independent variables.  In other words, a single variable might be weakly 
associated with the response variable, but when combined with other 
variables it can become an important predictor.  For the logistic regression 
a forward stepwise likelihood ratio method was used to select variables. 
The results from the logistic regression are presented in table 4.7. Only
the weight variable was included as a predictor of death status. According
to the equation a decrease in the weight of a patient by one unit (kg) 
increases the odds of death by 0,952.
Table 4.7: Variables in the logistic regression equation
Variables in the Equation
-.049 .004 193.987 1 .000 .952weight_kgStep 1a
B S.E. Wald df Sig. Exp(B)
Variable(s) entered on step 1: weight_kg.a.
Inspection of the classification table, however, reveals that overall the
logistic equation can not be regarded as a sufficient model for predicting






























The cut v alue is .500a. 
4.2.3 Determine the correct mortality rate amongst lost to follow-up
patients 
The results show that amongst patients that were lost to follow-up, the
mortality rate was 39%. This can be contrast d against the mortality rate
for the patients attending the ARV clinic of 5,4%









4.2.4 Risk of death 
The risk of death for patients with a low CD4 is illustrated in table 4.9 and 


















Table 4.9: Risk of Death for Patients with low CD4 count 
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Computed only  f or a 2x2 tablea. 


















CHAPTER 5 – DISCUSSION 
 
5.1 Introduction 
The aim of this retrospective study was to identify factors that may predict 
mortality of individuals started on HAART and to formulate a guideline to assist 
health care workers to identify and better support patients at higher risk in a 
resource limited setting. 
 
Since the introduction of HAART, HIV has become a chronic illness with an 
unpredictable course. The factors studied showed little value as predictors of 
outcome but may highlight patients at higher risk and assist health care workers 
to plan their treatment accordingly.  
 
5.2 Identifying variables associated with low CD4 count 
The following factors could explain variation in CD4 count as they were more 
prominent in the patient group with CD4<50. 
 
5.2.1 Demographic variables 
5.2.1.1 Male gender 
More male patients were found in the CD4 <50 group which drew our attention to 
the possibility that more male patients presents late.   
These findings are consistent with other studies43, 44 which report that HIV-
infected men present later for care than women and are therefore at greater risk 
of an adverse clinical course. Men delay seeking health care and have poorer 
clinical outcomes due to lower CD4 counts because of their late presentation. 
“The fact that women seek care earlier, or are identified earlier might be due to 
the fact that women are more likely to be tested earlier for HIV at an antenatal 
clinic or by a health-care provider they have visited to seek treatment for a 














they are the primary caregivers and feel a greater responsibility for remaining 
healthy”43.
A cross-sectional survey of 129 patients in Venezuela found the main barriers to 
HIV testing, and therefore late presentation, to be “low knowledge of HIV/Aids, 
lack of awareness of the free HIV programme, lack of perceived risk of HIV-
infection, fear for HIV-related stigma, fear of lack of confidentiality at testing site 
and logistic barriers”. This study also found that heterosexual males to presented 
late compared to homosexual males and females44.
These concerns should be addressed by treatment programmes and
programmes adapted accordingly. Some health care providers have altered their
clinic times so that patients do not need to take time off work to attend health
care facilities. There is also merit in having clinics at the work place but the fear
of stigmatisation should be addressed and confidentiality ensured. Home-based
care programmes can also be of great value, because part of the service is to
identify other ill patients in the household and educate the family, hoping to
promote awareness and prevent late presentation.
5.2.1.2 Low body weight 
The literature reviewed observes that weight loss has been described in many
patients with advanced HIV infection. From the statistical analyses the conclusion
was drawn that the patients in the CD4 <50 group had a lower mean body
weight. The literature further indicates various reasons for decrease in body
weight which include: malabsorption associated with infective diarrhoea, 
increased metabolic rate, decreased intake due to anorexia, oropharyngeal or 
















This indicates the need to do routine weight monitoring and recording at each 
follow-up visit so that unexplained or ongoing weight loss can be identified and 
further evaluated and underlying causes treated appropriately. 
 
 Interventions to combat weight loss advise “frequent small meals with high 
energy-foods such as porridge, potato and rice. A high protein diet should be 
encouraged, including eggs, milk, lentils, meat and fish”. Nutritional support 
programmes to provide patients with commercial high-energy and calorie 
preparations as food supplements also have a positive effect on weight loss 
management2.            
    
 Patients should be encouraged to eat a variety of food and include fresh fruits 
and vegetables in their daily diet. Community projects, such as food gardens, can 
have a valuable effect on nutrition. It should be emphasised that good nutrition 
and vitamin supplementation are advised alongside, not instead of HAART. 
 
5.2.2 Risk behaviour variables 
As this is a retrospective cohort study where the data reviewed came from 
patients attending the HIV clinic, only data that were available in the records 
could be analysed. The records indicated only two risk behaviour factors, 
smoking and alcohol use, which are general health risk factors. No sexual history 
was available and therefore could not be included in this study. The literature 
showed alcohol abuse to affect prognosis negatively in patients with HIV, one 
reason mentioned is nutrition associated with alcohol abuse. Alcohol abuse can 
also have a negative impact on adherence and therefore needs to be screened 
for before initiating HAART. The risk factors that were analysed showed no 




















5.2.3 Health variables 
5.2.3.1 Anaemia  
From the literature the question is asked whether anaemia is a marker of 
progressive HIV disease or not. Most studies concluded that anaemia is 
associated with a significant increased risk of death.  
 
Various etiologies could explain the anaemia, including: mycobacterium 
infections, parvovirus B19, micronutrient deficiencies, immunological 
myelosuppression, impaired erythropoietin production and blood loss from 
intestinal opportunistic disease. Most of the etiologies mentioned are seen in 
patients with advanced HIV. From the analysis done in this study the mean 
hemoglobin in the patients with CD4 count <50 (advanced HIV disease) were 
found to be 11,1 mmol/l.  This means hemoglobin is not as low as expected in 
the context of poverty, malnutrition and chronic illness. The reason for this can be 
that this is an urban population study group with probably had adequate nutrition 
and general health before becoming HIV-positive. 
 
The identification and treatment of anaemia can have a significant positive effect 
on patients‟ treatment outcome. Various opportunistic infections are mentioned 
as causes for anaemia and when treated correctly can decrease the burden of 
disease and positively influence the outcomes of HAART. Therefore health care 
workers should aim to identify the underlying etiology and treat patients 
accordingly.  
 
5.2.3.2 High viral count 
According to the literature, “a high viral count (RNA viral load quantification) 
indicates very active HIV disease and rapidly rising levels predict more rapid 
development of immune-deficiency”45. A higher viral count means a greater 















viral counts in patients with lower CD4 counts, correlates with literature on the 
subject and is seen as a risk factor for poor outcome.   
 
The use of HAART is a treatment modality aimed at stopping the progression of 
HIV disease by reducing the HIV viral load and thereby allowing for recovery of 
the immune system and subsequent reduction of HIV-related illness4. Viral load 
is also one of the follow-up markers to determine whether patients are 
responding to HAART. 
 
5.2.3.3 High AST and ALT levels 
Minor abnormalities of liver function tests (enzymes up to 3 times normal levels) 
are a common finding in patients with lower CD4 counts. The etiologies 
mentioned in the literature are malnutrition, an acute phase response and 
alcohol. If, however, “the ALT and AST is raised more than 3 times normal levels, 
other etiologies should be investigated like drug toxicity, viral hepatitis, other viral 
infections or liver involvement by other opportunistic infections”46. The finding of 
raised liver enzymes in the patients with severe immune suppression is therefore 
not surprising and can aid health care workers in suspecting and identifying co-
morbidities in patients with severe immune suppression. These patients should 
then undergo further special investigations and should then be treated according 
to the results. 
 
A baseline liver function can assist the health care professional to monitor 
patients for possible liver toxicity as a result of most drugs used in the treatment 
of HIV-related illness or HAART.  
 
5.3 Identifying factors that predict an increased risk of mortality 
 
Factors that may play a role in predicting the outcome of patients started on 


















5.3.1 Demographic variables 
5.3.1.1 Unemployment 
Unemployment is used as a marker of economic status. Patients may be 
unemployed due to illness with inadequate unemployment benefits or it may be 
difficult to find employment once the patient‟s health status has improved due to 
the high unemployment rate in South Africa. 
 
 A lack of income has various influences on disease progression. Firstly this 
group of patients has a higher risk of poor nutrition, which is also seen as a 
possible predictor of poor outcome on HAART. Secondly these patients may 
experience difficulties with transport which can lead to poor adherence and 
follow-up. Thirdly, living conditions may be hazardous and predispose patients to 
certain infections, like gastro-intestinal infections and tuberculosis. Assessing a 
patient‟s risk profile can lead to prevention of poor outcome of treatment by 
adjusting their treatment care plan and enhanced treatment support according to 
their needs. 
 
There is also the hypothesis that lower educational level may influence your 
understanding of the particular illness and therefore negatively influence 
treatment adherence. From this study no significant statistical correlation 
between educational level and poor outcome was shown. 
 
5.3.1.2 Low body weight 
The literature review showed evidence that weight loss in HIV-infected 
individuals to be predictive of decreased survival and increased their risk for 
developing opportunistic infections. The statistical analysis also showed a lower 
average weight associated with death cases. As previously mentioned this 


















5.3.2 Risk behaviour variables 
As mentioned in the literature review, an article by Palella et al.15 described the 
presence of co-morbid conditions, such as substance abuse and addiction as 
poor prognostic factors. Although no data were available on sexual risk 
behaviour, the general health variables (smoking and alcohol use) were included 
in this study. No statistical correlation was found between the risk behaviour 
mentioned and the outcome on HAART in this study. 
 
5.3.3 Health variables 
5.3.3.1 Anaemia  
From the literature anaemia was found to be one of the clinical manifestations of 
auto-immunity and one of the most common hematological abnormalities 
affecting 70-95% of HIV-positive individuals.  An association with increased risk 
of death was also found. 
 
The mean hemoglobin found from this analysis of data was 9,6 mmol/l in the 
patient group classified dead. The group classified alive had mean hemoglobin of 
13,2 mmol/l. The difference is statistically significant and shows an association 
between anaemia and increased risk of death. 
 
5.3.3.2 Low CD4 count 
The CD4 count is known for being a “marker of the state of immunity in patients 
with HIV infection and a good indicator of the risk for acquiring HIV-related 
opportunistic infections and other immune-deficiency disorders”45. The low CD4 
count correlates with an increase in immune suppression46. It is therefore also a 
possible predictor of outcome of HAART according to this study. Analysis of the 
cases reviewed in this study correlated with the literature. 
 














Viral load is a reliable predictor of disease progression and poor prognosis in HIV 
according to the relevant literature on the subject and predicts how rapidly the 
immune system will deteriorate. After the initiation of HAART it is a useful tool to 
evaluate the efficacy of treatment45. The possibility of predicting outcome of 
HAART pre-treatment is suggested from our statistical analysis but not 
concluded. 
Due to the overall low mortality rate of 5,4%, these factors (unemployment, low
body weight, low hemoglobin, low CD4 count and high viral load), as discussed
above, did not show to have any statistically significant predicting value for
mortality.
5.4 Determine correct mortality rate among lost to follow-up patients
Bisson et al. analysed a large public antiretroviral therapy programme in sub-
Saharan Africa and documents that of the total enrolled patients 16.6% was lost
to follow up soon after initiating HAART. The lost to follow up patients has a
mortality rate of 58.8%19.
The analysis showed a 39% mortality rate among lost to follow-up patients in this 
study. We are left with the question of whether these patients died after initiation
of HAART, before the next follow-up appointments, or subsequent to them
defaulting treatment. The other 61% of the lost to follow-up patients is of concern
because the question is asked whether they defaulted treatment or whether they
are receiving treatment at other facilities. Further studies could cast some light on
this subject and help health care providers to improve follow-up care. Lost to
follow-up data could assist health care workers in assessing adherence to
treatment. The high mortality rate among these patients highlights the need to
identify patients at risk early and adjust follow-up care accordingly. Strategies
that can be looked at may be a DOT (direct observed treatment programme) 















5.5 Limitations of the study 
This study only focuses on urban patients receiving care and HAART at Tshwane 
District Hospital‟s ARV clinic. 
This is a retrospective cohort study which utilised patient records to obtain data
and poor and incomplete data recording limited the analysis. This was most
prominent with regard to risk behaviour where the patient records only had
information on smoking and alcohol use, no sexual history was available. Further 
due to the design of this study the analysis is done at a specific point in time not
allowing time for follow-up data to show statistical significance.
Given the low mortality rate of patients started on HAART among the study
subjects, the study was under-powered to determine factors associated with
death.
A univariate analysis approach was followed. The limitation of such an analysis 
approach is the fact that it ignores the multivariate predictive capabilities of a
collection of weakly associated independent variables. In other words, a single
variable may be weakly associated with the response variable, but when
combined with other variables it can become an important predictor.
5.6 Suggestions for future research 
To improve future research studies and the building of predictive statistical 
models, it is imperative to ensure that accurate and complete record keeping 
(historical clinical information) takes place. It is also important to keep such 
records over a long period of time as this will improve reliability of studies still to 
be done. The researcher believes that the success of HAART also relies on the 
keeping of complete patient records to assist in the correct evaluation and 
















Future research can focus on building a model using multivariate predictive 
capabilities of collection of variables. 
 
















CHAPTER 6 – CONCLUSION AND RECOMMENDATION 
 
6.1 Conclusion 
This study aimed to identify factors/variables that could explain the variation in 
CD4 count among severe immune suppressed patients. Male gender, low body 
weight, high viral count, low hemoglobin level, high AST and ALT levels 
explained some of the variation in CD4 count and were more prominent in the 
CD4 < 50 group.  
 
Secondly this study aimed to identify factors that could predict the outcome of 
patients started on HAART. Factors that showed some significance were 
unemployment, lower body weight, a low CD4 count, high viral count and low 
hemoglobin level. Due to an overall low mortality rate of 5,4%, these factors did 
not show to have predicting value. HIV is  life-threatening illness with an 
unpredictable course. This low mortality rate shows that HAART is a very 
effective palliative treatment modality which has the potential to improve 
morbidity and prolong survival in patients with HIV. 
 
The third objective of this study was to determine the correct mortality rate 
among lost to follow-up patients. It showed a 39% mortality rate among lost to 
follow-up patients. It is believed that better surveillance and follow-up care may 
further improve the outcome of patients initiated on HAART. 
 
6.2 Recommendation 
The high prevalence of HIV in sub-Saharan Africa calls for an extensive ARV 
programme. Our programme needs to focus on the work–up and assessment of 
HIV patients prior to HAART initiation and to better follow-up care. Strategies 

















Health care workers/stakeholders will need to revise social support and follow-up 
care for patients in resource-poor settings with respect to improving their nutrition 
(poor nutrition was shown to have an influence on outcome of HAART) and 
possible assistance in general. 
 
Patients, who have lower CD4 counts and weight at baseline with low 
hemoglobin, should be closely monitored and additional support may be needed, 
clinical and non-clinical (e.g. home-based care). A focus on more regular contact 
with health care workers to identify opportunistic infections and detect side-effect 
of HAART early, for patients identified as at risk could improve outcomes of 
patients on HAART.  
 
Strategies that could be looked at may be a DOT (direct-observed treatment 
programme) system for HIV (as for TB) or home-based care may also assist to 
better monitor patients at risk. DOTs (directly-observed treatment short course) 
have been used to successfully deliver tuberculosis treatment in some of the 
world‟s poorest countries. “The main elements of DOTs include political 
commitment, case detection, standardised treatment with supervision and patient 
support, an effective drug supply and management system and a monitoring and 
evaluation system”47.  
 
Home-based care treatment could really make a difference in the care of HIV 
patients if successfully implemented and is based on the principles of good 
palliative care. The home-care based team should be coordinated by a 
professional nurse, assisted by trained community caregivers and other trained 
volunteers, with the support of the patient‟s doctor and other members of the 
interdisciplinary team who will be referred to as needed. The objectives of home 
visits should include the following: to introduce the HCW to the patient and 
family, explain the purpose of providing home care, make a holistic assessment 
of the patient and family,  plan care and support (involving family in all the stages 















family and plan to meet those needs, evaluate the need for human, material and 
social resources, identify actual and potential problems and develop realistic 
plans to alleviate these problems, assess whether or when patients need to be 
referred to other agencies,  manage pain and other symptoms, identify children in 
distress, provide counselling for patients and family, ensure a safe environment 
for patient and family (including infection control), assist with bereavement after 
the patient‟s death, empower patient and family to become as independent as 
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APPENDIX 1 – CLINICAL FEATURES OF HIV DISEASE 
Chapter 5: Clinical Features Of HIV Disease 
Table 5.3: WHO clinical staging of HIV/AIDS for adults and adolescents with 









Persistent qeneralized lymphadenopathy 
Unexplained moderate weight loss «10% of presumed or measured body weight) 
Recurrent respiratory tract infections (sinusitis, tonsillitis, otitis media and pharyngitis) 
Herpes zoster 
Angular cheilitis 
Recurrent oral ulceration 
Papular pruritic eruptions 
Seborrhoeic dermatitis 
Fungal nail infections 
Unexplained severe weight loss (>10% of presumed or measured body weight) 
Unexplained chronic diarrhea for longer than one month 
Unexplained persistent fever (above 37.5"C intermittent or constant, 
for longer than one month) 
Persistent oral candidiasis 
Oral hairy leukoplakia 
Pulmonary tuberculosis 
Severe bacterial infections (such as pneumonia, empyema, pyomyositis, 
bone or joint infection, meningitis or bacteraemia) 
Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis 
Unexplained anaemia «8.g/dl), neutropaenia «0.5 x 109 per litre) 
and/or chronic thrombocytopaenia «50 x 109 per litre) 
HIV wasting syndrome 
Pneumocystis pneumonia 
Recurrent severe bacterial pneumonia 
Chronic herpes simplex infection (orolabial, genital or anorectal 
of more than one month's duration or visceral at any site) 
Oesophageal candidiasis (or candidiasis of trachea, bronchi or lungs) 
Extrapulmonary tuberculosis 
Kaposi's sarcoma 
Cytomegalovirus infection (retinitis or infection of other organs) 
Central nervous system toxoplasmosis 
HIVencephalopathy 
Extrapulmonary cryptococcosis including meningitis 




Disseminated mycosis (extrapulmonary histoplasmosis or coccidiomycosis) 
Recurrent septicaemia (including non-typhoidal Salmonella) 
Lymphoma (cerebral or 8-cell non-Hodgkin) 
Invasive cervical carcinoma 
Atypical disseminated leishmaniasis 
Symptomatic HIV-associated nephropathy or symptomatic HIV-associated 
cardiomyopathy 















APPENDIX 2 – DATA EXTRACTION SHEET 
         
File Number       Viral Load     
         
Identity Number        Viral Load Log     
         
Date of 
Birth        Serum-albumin    
         
Educational Level      
Hemoglobin 
Level    
         
Racial 
Group        Platelet Count    
         
Employment         AST    
         
Marital Status       ALT    
         
Gender        TB Status    
         
Age       
Date initiation  
HAART     
         
Weight       Dead     
         
Smoker       Date of death     
         
Alcohol / Abuse       Cause of death     
         
Drug Abuse        Status Disclosure     
         
CD4 Count    %   Loss to Follow-up     
         
CD4 Count    Cell/ul   Comment:   
            
WHO Clinical Stage Recorded           
           
Stage           
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APPENDIX 6 – VARIABLES RECORDED 
The variables or factors recorded in the tool were: 
 age in completed years
 gender (male, female)
 race (black African, coloured, Indian, white)
 educational level (no education, primary, secondary, post matric)
 residence (urban, rural)
 weight in kilograms at HAART initiation
 total CD4 count (at HAART initiation)
 Viral load at HAART initiation
 Hemoglobin level
 Platelet count
 Liver function (with emphasis on AST and ALT levels)
 Serum-albumin (not routinely done at TDH)
 TB status (positive, negative, unknown)
 Smoke (yes, no)
 Alcohol abuse (yes, No)
 WHO stage of HIV disease (I-IV)
 Emotional and social support (noted as disclosure of HIV status)
 Lost to follow up, and
 Date HAART was initiated
 Survival status (died/ alive)
 Date of death (where indicated)
 Cause of death (natural/ unnatural)
